COBRA

Key terms image

COBRA Notification statement

A COBRA notification statement in insurance refers to a notice provided by employers to employees who are eligible for continued health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (COBRA).COBRA provides individuals with the option to continue their group health insurance coverage for a limited time after certain qualifying events, such as job loss or reduction in work hours.

COBRA Qualifying event

A COBRA qualifying event in insurance refers to a specific event that results in an individual's eligibility for continued health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act(COBRA). COBRA provides individuals with the option to continue their group health insurance coverage for a limited time after certain qualifying events, such as job loss or reduction in work hours. 

Consolidated Omnibus Budget Reconciliation Act (COBRA)

The Consolidated Omnibus Budget Reconciliation Act (COBRA)is a federal law that provides individuals with the option to continue their group health insurance coverage for a limited time after certain qualifying events, such as job loss or reduction in work hours. COBRA allows individuals to maintain their health insurance coverage during a period of transition, and ensures that they have access to the same benefits and coverage as they did when they were employed.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.